-
Microbot Medical plans full market release of robotic system in Q2 2026
-
Roth/MKM Starts Microbot Medical (MBOT) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Emory University Hospital adopts Microbot Medical's robotic system
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Microbot Medical begins limited US release of robotic system
-
Microbot Medical to showcase LIBERTY system at oncology meeting
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Microbot Medical partners with logistics provider for LIBERTY system launch
-
Microbot Medical (MBOT) files for 14.69M share offering by selling stockholders
-
Microbot Medical (MBOT) files for 900K share offering by selling stockholders
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Microbot Medical completes first closing of preferred option exercise
-
Microbot Medical exercises preferred options for up to $29.2 million
-
Microbot Medical (MBOT) PT Raised to $12 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Microbot Medical appoints Christina Bailey as VP of sales
-
Microbot Medical (MBOT) Granted New Patent in China
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Microbot Medical (MBOT) Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of LIBERTY Endovascular Robotic System
-
Microbot Medical (MBOT) Selected for Preliminary Inclusion to Russell Microcap Index
-
Microbot Medical (MBOT) adds to commercial leadership team
-
H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)
-
Microbot Medical (MBOT) Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
-
Microbot Medical (MBOT) Files for 12.54M Share Offering by Selling Stockholders
-
Microbot Medical (MBOT) Announces 6.1M Share Offering at $2.13/sh
-
Microbot Medical (MBOT) regains NASDAQ compliance
-
Microbot Medical (MBOT) PT Raised to $9 at H.C. Wainwright
-
Microbot Medical (MBOT) Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
-
Microbot Medical (MBOT) Announces 3.79M Share Offering at $2.27/sh
-
Microbot Medical (MBOT) Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
-
Microbot Medical (MBOT) Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System
-
Microbot Medical (MBOT) Announces the Successful Completion of its Pivotal Human Clinical Trial
-
Microbot Medical (MBOT) Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
-
Microbot Medical (MBOT) Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY Endovascular Robotic System
-
Microbot Medical (MBOT) Partners with Baptist Hospital of Miami to Participate in its Trial
-
Microbot Medical (MBOT) Partners with Brigham and Women's Hospital for Human Clinical Trial
-
Microbot Medical (MBOT) Files for 3.21M Share Offering by Selling Stockholders

